Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Napazimone · KL-1333, NAP-09M

Small molecule · developed by Pharming Technologies B.V.

Phase 2 Most advanced trial
PHAR Developer
2 Registered trials

What is Napazimone?

Napazimone (KL1333) is an oral agent given twice daily, with doses titrated to the maximum well tolerated dose. It is studied in primary mitochondrial disease and mitochondrial diseases.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
KL-1333, NAP-09M
Drug type
Small molecule
Therapy area
Metabolic
Developer
Pharming Technologies B.V. (PHAR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
NA2ZOL5UGM

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07514338 Phase 2 Mitochondrial Diseases Recruiting PHAR
NCT05650229 Phase 2 Primary Mitochondrial Disease Recruiting PHAR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Mitochondrial DiseasesPrimary Mitochondrial Disease

More from Pharming Technologies B.V.

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PHAR page.

Follow PHAR, the company behind Napazimone

See PHAR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PHAR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.